Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

Accelerated aspiration with Q™ catheter: An in vitro study
Reymond, Philippe , Contreras, Mayra, Brina, Olivier , Langston, Trent, Brinjikji, Waleed , Wainwright, J, Machi, Paolo , Reymond, Philippe , Chesler, Naomi C.

Interventional Neuroradiology | November 6, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15910199241273974 | PMID 39501852 Get It

Background and Purpose Thrombectomy in distal, medium vessels is a topic of increasing interest. To date, there are few in vitro studies focused on performance of ≤5F catheters in medium vessels. The purpose of this study is to compare the performance of the 3F, 4F, and 5F MIVI Neuroscience Q Catheters versus Penumbra 3F, 4F, and MicroVention Sofia 5F Catheters. Methods Using in vitro methods, we assessed and compared the following parameters: aspiration flow rates, clot uncorking forces, impulse, and clot ingestion. For flow rate, each aspiration catheter was immersed in a cylindrical container. Flow rate at one second was used to calculate impulse. For clot uncorking force, the force required to disengage a catheter from a simulated clot was recorded. For ingestion, we measured time to ingest soft and medium stiffness synthetic clots. Results The measured flow rates without a stent retriever for the Q3, Q4, and Q5 catheters were 3.54 ml/s, 5.32 ml/s, and 6.87 ml/s. The measured flow rates without a stent retriever for the 3MAX, 4MAX, and 5F Sofia were 1.46 ml/s, 2.56 ml/s, and 1.73 ml/s. The impulse calculated for one second was 26 mNs for Q5 vs 9 mNs for Sofia 5, 35 mNs for Q4 vs 15 mNs for 4Max< and 35 mNs for Q3 vs 9 mNs for 3Max. The average system ingestion for Q was significantly faster than the competitive catheters. Conclusions The Q catheters demonstrated higher flow rates, higher uncorking force, and faster complete clot ingestion than competitive catheters.
Safe Options for the Treatment of Mothers and Babies with Pregestational Diabetes
Benhalima, Katrien , Mathieu, Chantal , Napoli, Angela , Kudva, Yogish C. , Cypryk, Katarzyna , Hammond, Peter , Divakar, Hema , Hod, Moshe, Mathieu, Chantal , Cukierman‐Yaffe, Tali , Cyganek, Katarzyna

Diabetes Technology & Therapeutics | November 6, 2024 | Volume: 27 | Issue: 2 | Pages: 91-92

10.1089/dia.2024.0499 | PMID 39501847 Get It

Characterization and Efficacy of Autologous Serum-based Eyedrops for the Treatment of Severe Ocular Surface Disease
Arthurs, Jennifer R. , Stewart, Michael W., Hassoun, Shaimaa, Moerer, Ryan T., Miller, Darby D. , Heckman, Michael G. , Shapiro, Shane A.

Journal of Cornea and Ocular Surface | November 6, 2024 | Volume: 1 | Issue: 3 | Pages: 149-156

10.4103/jcos.jcos_6_24 Get It

Abstract Background: Chronic dry eye disease (CDED) is a condition of the ocular surface that causes discomfort, visual disturbance, conjunctival injection, and photophobia. A debilitating form of CDED in patients undergoing allogeneic bone marrow transplant results from ocular graft versus host disease (oGVHD). Autologous serum eye drops (ASED) have beneficial effects on the ocular surface. The aim of this study is to compare improvements in symptoms and function in a cohort of CDED patients with ocular GVHD treated with ASED and a cohort of CDED without GVHD (non-GVHD). We additionally report on some of the biologic characteristics of one specific ASED formulation. Materials and Methods: A total of 71 patients seen in a multi-specialty ophthalmology practice in a university hospital setting receiving ASEDs underwent ocular surface disease index (OSDI) and visual function questionnaire measurements at baseline, 3 months, and 6 months. Twenty-four ASED samples were studied for biomarkers. Results: Compared to baseline, OSDI scores significantly decreased after 3 and 6 months of ASED treatment in both oGVHD and non-GVHD CDED groups. Additionally, visual function questionnaire-25 (VFQ-25) subscales (ocular pain, distance activity, driving, role difficulties, dependency, and mental health) were significantly improved at 3 months and 6 months, and social functioning was improved at 6 months. The majority of patients in both groups had severe disease. Improvements in patient-reported outcomes were greater in the oGHD CDED group than in the non-GVHD CDED group There were no reported complications. Conclusion: ASED is safe and effective in patients with CDED due to oGVHD and non-GVHD. Those with oGVHD had greater improvements. These findings potentiate the wider adoption of this therapy in CDED patients and warrant additional studies into the biochemical makeup of ASED.
The Combined Inhibition of SREBP and mTORC1 Signaling Synergistically Inhibits B‐Cell Lymphoma
Zhu, Zhenhan, Jiang, Wenxia , Zhou, Jiehao , Maldeney, Alexander R. , Liang, Jingru , Luo, Wei , Luo, Wei , Zhu, Zhenhan, Yang, Jing

Cancer Medicine | November 6, 2024 | Volume: 13 | Issue: 21 | Pages: No page available

10.1002/cam4.70342 | PMID 39501600 Get It

ABSTRACT Background The sterol regulatory element‐binding protein (SREBP) pathway is essential for maintaining sterol homeostasis during B cell activation and germinal center B cell proliferation. However, its potential as a therapeutic target to treat B‐cell lymphoma remains unclear. Methods We examined SREBP protein expression in human B‐cell lymphoma samples using immunohistochemistry. Additionally, we conducted in vitro studies using SREBP signaling inhibitors in combination with rapamycin to assess their effects on cell proliferation and lipid metabolism in B‐cell lymphoma cells. Results Our analysis revealed high levels of SREBP2 protein expression in human B‐cell lymphoma samples. Inhibiting SREBP signaling or its downstream target HMG‐CoA reductase (HMGCR) with Fatostatin or Simvastatin effectively suppressed B‐cell lymphoma cell proliferation. However, B‐cell lymphoma cells responded to statin treatment by activating the mTORC1‐pS6 pathway, suggesting a compensatory mechanism to overcome statin‐induced cell cycle arrest. Combining low‐dose statin treatment with the mTOR inhibitor rapamycin produced a synergistic effect, significantly inhibiting B‐cell lymphoma proliferation, cell cycle progression, and lipid raft formation. Conclusions These results highlight the potential of a combined therapeutic approach targeting both SREBP and mTORC1 as a novel strategy for treating B‐cell lymphoma.
Checkpoint inhibition in macroglobulinaemia
Kapoor, Prashant

British Journal of Haematology | November 6, 2024 | Volume: 205 | Issue: 6 | Pages: 2128-2130

10.1111/bjh.19844 | PMID 39501514 Get It

Waldenström macroglobulinaemia (WM) is a unique, cluster of differentiation (CD) 20+ B‐cell malignancy, with a characteristic immunoglobulin M‐secreting lymphoplasmacytic bone marrow infiltrate that is bolstered by a highly supportive microenvironment, including upregulated programmed death 1 expression. However, the impact of checkpoint inhibition in WM is unclear. Commentary on: Kothari et al. PembroWM: A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's macroglobulinaemia. Br J Haematol 2024; 205: 2273‐2281 .
Modeling Fibrin Accumulation on Flow‐Diverting Devices for Intracranial Aneurysms
Cebral, Juan R. , Mut, Fernando , Löhner, Rainald , Marsh, Laurel , Chitsaz, Alireza , Bilgin, Cem , Bayraktar, Esref Alperen , Kallmes, David F. , Kadirvel, Ramanathan , Bayraktar, Esref Alperen , Kallmes, David, Marsh, Laurel , Cebral, Juan R , Bilgin, Cem

International Journal for Numerical Methods in Biomedical Engineering | November 6, 2024 | Volume: 40 | Issue: 12 | Pages: No page available

10.1002/cnm.3883 | PMID 39501466 Get It

ABSTRACT The mechanisms leading to aneurysm occlusion after treatment with flow‐diverting devices are not fully understood. Flow modification induces thrombus formation within the aneurysm cavity, but fibrin can simultaneously accumulate and cover the device scaffold, leading to further flow modification. However, the interplay and relative importance of these processes are not clearly understood. A computational model of fibrin accumulation and flow modification after flow diversion treatment of cerebral aneurysms has been developed under the guidance of in vitro experiments and observations. The model is based on the loose coupling of flow and transport‐reaction equations that are solved separately by independent codes. Interaction or reactive terms account for thrombin production from prothrombin stimulated by thrombogenic metallic wires and inhibition by antithrombin as well as fibrin production from fibrinogen stimulated by thrombin and flow shear stress, and fibrin adhesion to device wires and already attached fibrin. The computational model was demonstrated and tested on idealized vessel and aneurysm geometries. The model was able to reproduce the salient features of fibrin accumulation after the deployment of flow‐diverting devices in idealized in vitro models of cerebral aneurysms. Namely, fibrin production in regions of high shear stress, initial accumulation at the inflow zone, and progressive occlusion of the device and corresponding flow attenuation. The computational model linking flow dynamics to fibrin production, transport, and adhesion can be used to investigate and better understand the effects that lead to fibrin accumulation and the resulting aneurysm inflow reduction and intra‐aneurysmal flow modulation.
A Case of Stiff Person Syndrome
Menville, Jesse E. , Richardson, Edward P. , Reed, Griffin , Neill, Marguerite A., Naqvi, Syed Muhammad Zulfiqar Hyder , Reed, Griffin J , Naqvi, Syed R.

Annals of Internal Medicine: Clinical Cases | November 5, 2024 | Volume: 3 | Issue: 11 | Pages: No page available

10.7326/aimcc.2024.0188 Get It

Comparative Proteomics Highlights that GenX Exposure Leads to Metabolic Defects and Inflammation in Astrocytes
Abu-Salah, Abdulla , Cesur, Müberra Fatma , Anchan, Aiesha , Langley, Monica R. , Reina-Gonzalez, Pablo , Strazdins, Rachel, Çakır, Tunahan , Sarkar, Souvarish , Strazdins, Rachel , Sarkar, Souvarish , Ay, Muhammet , Shah, Ahmed, Çakır, Tunahan

Environmental Science & Technology | November 5, 2024 | Volume: 58 | Issue: 46 | Pages: 20525-20539

10.1021/acs.est.4c05472 | PMID 39499804 Get It

Optimizing Anti–Myelin-Associated Glycoprotein and IgM-Gammopathy Testing for Neuropathy Treatment Evaluation
Murray, David , Gorsh, Amy P., Shelly, Shahar , Dubey, Divyanshu , Pinto, Marcus Vinícius , Ansell, Stephen M. , Skolka, Michael , Swart, Grace , Mauermann, Michelle L. , Mills, John R. , Klein, Christopher J , Triplett, James D, Shahar, Shelly , Dubey, Divyanshu , Pinto, Marcus V , Skolka, Michael P , Mauermann, Michelle L , Mills, J R , Klein, Christopher J. , Triplett, James

Neurology | November 5, 2024 | Volume: 103 | Issue: 11 | Pages: No page available

10.1212/wnl.0000000000210000 | PMID 39499873 Get It

Prescription Testosterone Is Associated With an Increased Risk of Anterior Cruciate Ligament Injury
Brinkman, Joseph C. , Holle, Alejandro M. , Paul, Benjamin C. , Payne, Camryn S, Tummala, Sailesh V. , Haglin, Jack M. , Chhabra, Anikar , Payne, Cynthia S. , Chhabra, Anikar , Holle, Alejandro , Tummala, Sailesh V , Payne, Camryn S

Arthroscopy | November 5, 2024 | Volume: 41 | Issue: 7 | Pages: 2440

10.1016/j.arthro.2024.10.032 | PMID 39510204 Get It

Purpose To characterize the relationship between testosterone replacement therapy (TRT) and anterior cruciate ligament (ACL) injuries. Methods A retrospective cohort study using a large insurance database was conducted. Patients who were prescribed TRT for at least 3 months were matched with controls who were not prescribed TRT. Rates of ACL tears were compared between the cohorts. Multiple subgroups were created based on age (<25, 25‐35, 36‐45, 46‐55, 56‐65, and 65+ years). Multivariable logistic regressions were performed to determine the association of TRT with ACL tears while accounting for demographic variables and comorbidities. Results After matching, there were 160,839 patients in both the TRT cohort and the control cohort. The incidence of ACL injuries was 17.8 per 10,000 person‐years (95% confidence interval [CI]: 16.4‐19.2) for patients who were prescribed TRT and 4.9 per 10,000 person‐years (95% CI: 4.1‐5.7) for controls ( P < .001). Within 2 years of filling a testosterone prescription for at least 3 months, 572 (0.35%) patients experienced an ACL injury compared to only 157 (0.10%) controls during the same follow‐up period (odds ratio: 2.77; 95% CI: 2.26‐3.42, P < .001). When stratified by age, all groups except the <25 years of age group demonstrated a significantly higher rate of ACL tears (odds ratio 3.91‐12.3, P < .001‐.009). When separated by sex, males on TRT were 3.13 (95% CI: 2.50‐3.93, P < .001) times more likely while females on TRT were 1.94 (95% CI: 1.13‐3.41, P = .018) times more likely to experience an ACL injury compared to controls. Conclusions This study found that patients prescribed at least 3 months of TRT had a significantly higher incidence of ACL injuries compared to controls within a 2‐year follow‐up period. Level of Evidence Level III, retrospective comparative study.